Search Results 351-360 of 16681 for anti-TNF drugs

1. A Study to Evaluate TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD) - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy ... By condition, treatment or drug name. Search tips ... This includes anti-tumor necrosis factor-alpha (TNF ...

2. Antidepressants: Can they stop working? - Mayo Clinic

   Underlying health conditions, such as hypothyroidism, can cause or worsen depression. A new medicine. Some medicines for conditions not related to depression ...

3. Nortriptyline (oral route) - Side effects & dosage - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

4. A Study to Evaluate the Immune Response to Anti-HER2 Therapies - Mayo Clinic

   Scheded to start new anti=HER2 therapy/therapies. Provide written informed consent. Willingness to provide blood samples for correlative research purposes ...

5. Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) - Mayo Clinic

   Treatment with an anti-complement therapy or with Zileuton (Zyflo) within the last three months prior to baseline (Day 1). OCS dose no more than 0.3mg/kg ...

6. Radiopharmaceuticals Clinical Trials - Mayo Clinic Research

   ... anti-cancer treatment and have a positive 68Ga-PSMA-11 PET scan. The purpose of this study is to learn if the study drug, [225Ac]Ac-PSMA-R2, is safe and ...

7. A Study to Evaluate the Safety and Effectiveness of BMS-986165 in Subjects with Moderate-to-Severe Ulcerative Colitis (UC) - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... anti-tumor necrosis factor (TNF)-α agents, integrin inhibitor. Exclusion ...

8. Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis - Mayo Clinic

   ... therapy. Rectal products; Biological agents: Anti-tumour necrosis factor (anti - TNF) therapy and / or vedolizumab; are not permitted within 8 weeks of the ...

9. Targeting VEGF-Independent Proangiogenic Pathways in Anti-VEGF Refractory Renal Cell Cancer - Tumor Angiogenesis and Vascular Biology Laboratory - Mayo Clinic Research

   Mukhopadhyay's lab is developing novel treatment strategies to target these pathways for refractory and highly aggressive tumor types and for sarcomatoid renal ...

10. Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer - Mayo Clinic

    Drugs used in chemotherapy ... TNF] agents) within 2 weeks prior to cycle 1, day 1: ... A stable regimen of highly active anti-retroviral therapy (HAART); ...